Currently out of the existing stock ratings of Michael Yee, 312 are a BUY (77.61%), 89 are a HOLD (22.14%), 1 are a SELL (0.25%).

Michael Yee

Work Performance Price Targets & Ratings Chart

Analyst Michael Yee, currently employed at UBS, carries an average stock price target met ratio of 59.23% that have a potential upside of 31.62% achieved within 284 days.

Michael Yee’s has documented 776 price targets and ratings displayed on 50 stocks. The coverage is on Healthcare, Industrials, Pharmaceuticals sectors.

Most recent stock forecast was given on SDGR, Schrodinger at 13-Aug-2026.

Wall Street Analyst Michael Yee

Analyst best performing recommendations are on IMRX (IMMUNEERING CORP).
The best stock recommendation documented was for IMRX (IMMUNEERING CORP) at 6/25/2025. The price target of $3.5 was fulfilled within 2 days with a profit of $0.48 (15.89%) receiving and performance score of 79.47.

Average potential price target upside

of $162.27 (77.17%) on ASMB (ASSEMBLY BIOSCIENCES).
of $70.62 (35.02%) on AMGN (AMGEN).
of $40.25 (15.85%) on BIIB (BIOGEN).

ACOR Acorda Therapeutics ADGI Adagio Therapeutics ALGS Aligos Therapeutics AMRN Amarin PLC ASMB Assembly Biosciences EPZM Epizyme ESPR Esperion Therapeutics GILD Gilead Sciences ICPT Intercept Pharmaceuticals MRNA Moderna PRTA Prothena plc SDGR Schrodinger AMGN Amgen VRTX Vertex Pharmaceuticals AXON Axon Enterprise BIIB Biogen BMRN Biomarin Pharmaceutical CELG Celgene CERE Cerevel Therapeutics Holdings FGEN FibroGen ONCE Spark Therapeutics ODT Odonate Therapeutics ZLAB Zai Lab Ltd SRRK Scholar Rock Holding Corp VTYX Ventyx Biosciences NUVB Nuvation Bio IMCR Immunocore Holdings Ltd LIAN LianBio ADR ALLO Allogene Therapeutics KOD Kodiak Sciences ALXO Alx Oncology Holdings BEAM Beam Therapeutics RXDX Prometheus Biosciences DNLI Denali Therapeutics IMRX Immuneering Corp MORF Morphic OLMA Olema Pharmaceuticals CRGX CARGO Therapeutics, Common Stock ABUS Arbutus Biopharma Corp AKRO Akero Therapeutics FATE Fate Therapeutics ABBV AbbVie ACLX Arcellx ANAB AnaptysBio EXEL Exelixis FG F&G Annuities & Life INBX Inhibrx ORKA Oruka Therapeutics PTI Proteostasis Therapeutics PFE Pfizer

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Raghuram Selvaraju (HC WAINWRIGHT)